Immunome (IMNM) Common Equity (2019 - 2026)
Immunome's (IMNM) quarterly Common Equity came in at $588.7 million in Q1 2026, up 91.68% YoY from $307.1 million in Q1 2025, and down 7.2% on a QoQ basis from $634.3 million in Q4 2025.
Immunome (IMNM) Common Equity (2019 - 2026) Analysis & Trends
Immunome (IMNM) has 8 years of Common Equity data on file, last reported at $588.7 million in Q1 2026.
- Quarterly Common Equity rose 91.68% year-over-year to $588.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $588.7 million (up 91.68% YoY) and the FY2025 annual result came in at $634.3 million, up 250.15% from the prior year.
- Common Equity eased to $588.7 million in Q1 2026, from $634.3 million in the prior quarter.
- In the past five years, Common Equity ranged from a high of $634.3 million in Q4 2025 to a low of $6.1 million in Q3 2023.
- A 5-year average of $191.5 million and a median of $181.2 million in 2024 frame the typical range for Common Equity.
- Annual changes were most pronounced in 2023 — Common Equity plunged 73.68% — and 2024, when it surged 3436.97%.
- Tracing IMNM's Common Equity over 5 years: stood at $16.7 million in 2022, then soared by 619.88% to $119.9 million in 2023, then jumped by 51.12% to $181.2 million in 2024, then surged by 250.15% to $634.3 million in 2025, then decreased by 7.2% to $588.7 million in 2026.
- The last three Common Equity figures came in at $588.7 million (Q1 2026), $634.3 million (Q4 2025), and $263.9 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.61 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.79 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 757.49 Mn |
| 10 | Immunome | 3.09 Bn | 2.57 Bn | - | 525.08 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 525.08 Mn |
| Mar 31, 2026 | 588.69 Mn |
| Dec 31, 2025 | 634.34 Mn |
| Sep 30, 2025 | 263.92 Mn |
| Jun 30, 2025 | 269.27 Mn |
| Mar 31, 2025 | 307.13 Mn |
| Dec 31, 2024 | 181.17 Mn |
| Sep 30, 2024 | 214.91 Mn |
| Jun 30, 2024 | 253.84 Mn |
| Mar 31, 2024 | 285.57 Mn |
| Dec 31, 2023 | 119.88 Mn |
| Sep 30, 2023 | 6.08 Mn |
| Jun 30, 2023 | 9.34 Mn |
| Mar 31, 2023 | 13.86 Mn |
| Dec 31, 2022 | 16.65 Mn |
| Sep 30, 2022 | 23.08 Mn |
| Jun 30, 2022 | 30.28 Mn |
| Mar 31, 2022 | 37.87 Mn |
| Dec 31, 2021 | 48.19 Mn |
| Sep 30, 2021 | 54.79 Mn |